Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EBT (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed EBT for 13 consecutive years, with -$71.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT rose 6.86% to -$71.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$393.0 million, a 4.81% decrease, with the full-year FY2025 number at -$393.0 million, down 4.81% from a year prior.
  • EBT was -$71.7 million for Q4 2025 at Iovance Biotherapeutics, up from -$93.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$71.7 million in Q4 2025 to a low of -$118.1 million in Q4 2023.
  • A 3-year average of -$101.3 million and a median of -$107.2 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: skyrocketed 34.82% in 2024, then fell 11.27% in 2025.
  • Iovance Biotherapeutics' EBT stood at -$118.1 million in 2023, then surged by 34.82% to -$77.0 million in 2024, then rose by 6.86% to -$71.7 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's EBT are -$71.7 million (Q4 2025), -$93.7 million (Q3 2025), and -$109.7 million (Q2 2025).